Affiliations 

  • 1 Sumy State University, Sumy, Ukraine
  • 2 SUNY Upstate Medical University, Syracuse, New York, United States
  • 3 Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
  • 4 University of Debrecen-Faculty of Medicine, Debrecen, Hungary
  • 5 Faculty of Medicine and Health Sciences, University of Putra Malaysia, Serdang, Malaysia
  • 6 University of Louisville School of Medicine, Louisville, Kentucky, United States
  • 7 Liberty University College of Osteopathic Medicine, Lynchburg, Virginia, United States
  • 8 Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
  • 9 Lincoln Memorial University-DeBusk College of Osteopathic Medicine Harrogate, Harrogate, Tennessee, United States
  • 10 Department of Clinical Sciences, Division of Health Sciences, University of Monterrey, San Pedro Garza García, Nuevo León, Mexico
  • 11 Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia
  • 12 Deanship of Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • 13 Department of Biology, King Abdulaziz University, Jeddah, Saudi Arabia
  • 14 Glocal School of Life Sciences, Glocal University, Saharanpur, Uttar Pradesh, India
  • 15 Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany
  • 16 University of Sharjah, College of Health Sciences, and Research Institute for Medical and Health Sciences, Department of Medical Laboratory Sciences, Sharjah, United Arab Emirates
Biofactors, 2024 Jan 16.
PMID: 38226733 DOI: 10.1002/biof.2039

Abstract

Alzheimer's disease (AD) constitutes a multifactorial neurodegenerative pathology characterized by cognitive deterioration, personality alterations, and behavioral shifts. The ongoing brain impairment process poses significant challenges for therapeutic interventions due to activating multiple neurotoxic pathways. Current pharmacological interventions have shown limited efficacy and are associated with significant side effects. Approaches focusing on the early interference with disease pathways, before activation of broad neurotoxic processes, could be promising to slow down symptomatic progression of the disease. Curcumin-an integral component of traditional medicine in numerous cultures worldwide-has garnered interest as a promising AD treatment. Current research indicates that curcumin may exhibit therapeutic potential in neurodegenerative pathologies, attributed to its potent anti-inflammatory and antioxidant properties. Additionally, curcumin and its derivatives have demonstrated an ability to modulate cellular pathways via epigenetic mechanisms. This article aims to raise awareness of the neuroprotective properties of curcuminoids that could provide therapeutic benefits in AD. The paper provides a comprehensive overview of the neuroprotective efficacy of curcumin against signaling pathways that could be involved in AD and summarizes recent evidence of the biological efficiency of curcumins in vivo.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.